CHANGE IN RATINGS, EPS
Accenture (ACN) estimates, target upped at Goldman.ACN estimates were boosted through 2013. Company is realizing higher sales and margins. Buy rating and new $62 price target.
Apple (AAPL) estimates boosted at Jefferies through 2012. iPhone strength should offset any iPad cuts. Buy rating and $500 price target.
Apple estimates increased at Needham through 2012. Mac and iPad sales should drive growth.
Assured Guaranty (AGO) estimates cut at UBS through 2011. Lower discount rates on loss reserves. Maintain $28 price target and Buy rating.
Biomarin Pharmaceuticals (BMRN) upgraded at Deutsche from Hold to Buy. $40 price target. Company has a promising pipeline and multiple near-term catalysts.
Boston Scientific (BSX) target reduced at Goldman to $6.70. Consensus sales expectations appear too high. Neutral rating.
Charles Schwab (SCHW) estimates lowered at JMP through 2012. Company is realizing lower asset fees and net interest income. Market Perform rating.
Comerica (CMA) upgraded at Wells from Underperform to Market Perform. Valuation call, as the stock is down 22% over the past 7 weeks.
ConocoPhillips (COP) estimates increased at UBS through 2012. Shutting down unprofitable refinery. Maintain $64 price target and Neutral rating.
Coventry Health (CVH) estimates increased at Morgan Stanley through 2013. $39 price target. Company is cutting costs and looking to expand its Medicaid business in Kentucky. Overweight rating.
Equity One (EQY) estimates cut at UBS through 2012. Reflect! ing dilu tion from sale to Blackstone. Maintain $18 price target and Neutral rating.
Huntington Ingalls (HII) rated new Sell at Goldman. $21 price target. Company is leveraged to a shrinking U.S. defense budget.
Jabil Circuit (JBL) estimates, target raised at Citigroup.Shares of JBL now seen reaching $22. Estimates also raised on impressive ability to perform in tough macro. Maintain Hold rating.
Jabil Circuit estimates, target raised at UBS.Shares of JBL now seen reaching $22. Estimates also raised on better than expected results in DMS and HVS segments. Maintain Buy rating.
KLA-Tencor (KLAC) rated new Neutral at JP MorganKLAC was initiated with a Neutral rating. Company has solid margins, but exposure to foundry customers. $43 price target.
Lam Research (LRCX) rated new Overweight at JP Morgan. $56 price target. Company will likely repurchase a lot of its shares.
Masco (MAS) upgraded at UBS from Sell to Neutral. $7.50 price target. Impact of weaker macro backdrop already reflected in valuation.
Mead Johnson Nutrition (MJN) downgraded at Citigroup from Buy to Hold. $80 price target. Valuation call as stock has limited upside.
Mead Westvaco (MWV) upgraded at JP Morgan from Neutral to Overweight. $30 price target. Company is a defensive play an offers a solid dividend yield.
Mylan (MYL) rated new Hold at Canaccord. $21 price target. Near term earnings risk tempers otherwise upbeat view.
Novellus Systems (NVLS) rated new Overweight at JP Morgan. $35 price target. Memory business should continue to drive growth and the company will likely return cash to! shareho lders.
Oneok (OKE) estimates, target raised at Morgan Stanley. Shares of OKE now seen reaching $82. Estimates also increased, given increased growth visibility. Equal-weight rating.
Paccar (PCAR) estimates, target cut at Credit Suisse.PCAR estimates were reduced through 2013. Truck sales should be slower in Europe. Neutral rating and new $39 price target.
Perrigo (PRGO) rated new Hold at Canaccord. $105 price target. Solid defensive play in a tough tape, but reflected in the stock price already.
Perrigo estimates, target raised at Goldman. Shares of PRGO now seen reaching $110. Estimates also increased, as the company is realizing higher margins. Neutral rating.
Perrigo estimates, target raised at UBS. Shares of PRGO now seen reaching $115. Estimates also raised as double digit earnings growth seems achievable. Maintain Buy rating.
Philip Morris (PM)estimates, target cut at CitigroupShares of PM now seen reaching $68. Estimates also lowered on F/X headwinds. Maintain Hold rating.
Polo Ralph Lauren (RL) downgraded at Citigroup from Buy to Hold. $160 price target. Ongoing inflation concerns and valuation.
Qualcomm (QCOM) estimates increased at Sterne Agee through 2013. Company is well positioned for customers' new product launches. Buy rating and $67 price target.
Silgan (SLGN) rated new Neutral at JP Morgan. Valuation call, based on a $44 price target.
Smithfield Foods (SFD) upgraded at BMO from Market Perform to Outperform. $24 price target. Stock is already factoring in lower hog prices.
Sysco (SYY) rated new Underperform at Credit Suisse. ! $23 pric e target. Growth is maturing and consensus estimates appear to optimistic.
Teva Pharmaceutical (TEVA) rated new Buy at Canaccord. $52 price target. See an inflection point in 2012 on all fronts with sentiment at its lows.
Texas Instruments (TXN) estimates upped at Evercore through 2012. NSM purchase should add to earnings. Overweight rating and $33 price target.
Walgreens (WAG) estimates cut at Morgan Stanley through 2013, Morgan Stanley said. Express scripts exit continues to weigh on results. Overweight rating and $45 price target.
Watson Pharmaceuticals rated new Buy at CanccordWPI was initiated with a Buy rating. $85 price target. Solid pipeline with near term catalysts.
End of report.
No comments:
Post a Comment